Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

JW (Cayman) Therapeutics Co. Ltd. (JNY) AI Stock Analysis

0 Followers
DE:JNY

JW (Cayman) Therapeutics Co. Ltd.

(Frankfurt:JNY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue and Gross Margin ImprovementThe sharp 2025 revenue rebound, together with improved gross margin, indicates stronger commercial traction and better economics on sales. If maintained, this combination can expand the resource base available for clinical development, commercialization, and operating leverage over the next several quarters.
Negative Factors
Deep and Persistent LossesThe company remains far from break-even despite improved revenue and narrower losses. Deep negative profitability limits internally generated funding, makes operating performance highly dependent on future growth, and could constrain the ability to sustain investment across its cell and gene therapy pipeline.

JW (Cayman) Therapeutics Co. Ltd. (JNY) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%DE:JNY-27.69%EWG+5.12%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.06B
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-2.8
Beta (1Y)
0.82
Revenue Growth
55.89%
EPS Growth
47.77%
Country
Germany
Employees
303
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

JW (Cayman) Therapeutics Co. Ltd. Business Overview & Revenue Model

Company Description

JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through tr...

JW (Cayman) Therapeutics Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:JNY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:9966HK:996652NeutralHKD 6.09B-30.93-10.27%―-31.77%-177.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:2181HK:218151NeutralHKD 1.81B18.2748.25%―88.38%―
HK:2616HK:261647NeutralHKD 8.63B-17.28-43.54%―116.67%-0.42%
HK:1541HK:154144NeutralHKD 1.18B-4.40-32.32%―28.93%27.27%
HK:2171HK:217139UnderperformHKD 6.69B-61.53-9.45%―68.12%81.84%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:JNYHK:9966HK:2171HK:2181HK:2616HK:1541Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:JNY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:JNYJW (Cayman) Therapeutics Co. Ltd.0.28-0.09-24.60%
HK:9966Alphamab Oncology6.25-3.67-37.05%
HK:2171CARsgen Therapeutics Holdings Ltd.11.26-5.94-34.53%
HK:2181Mabpharm Limited0.44-0.08-15.38%
HK:2616CStone Pharmaceuticals5.48-0.04-0.72%
HK:1541ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H2.74-4.86-63.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.